The group III
metabotropic glutamate receptor 7 (
mGluR7) has been implicated in many neurological and
psychiatric diseases, including
drug addiction. However, it is unclear whether and how
mGluR7 modulates nucleus accumbens (NAc)
dopamine (DA),
L-glutamate or
gamma-aminobutyric acid (
GABA), important
neurotransmitters believed to be involved in such neuropsychiatric diseases. In the present study, we found that systemic or intra-NAc administration of the
mGluR7 allosteric agonist N,N'-dibenzyhydryl-ethane-1,2-diamine dihydrochloride (
AMN082) dose-dependently lowered NAc extracellular
GABA and increased extracellular
glutamate, but had no effect on extracellular DA levels. Such effects were blocked by (R,S)-
alpha-methylserine-O-
phosphate (
MSOP), a group III mGluR antagonist. Intra-NAc perfusion of
tetrodotoxin (TTX) blocked the AMN082-induced increases in
glutamate, but failed to block the AMN082-induced reduction in
GABA, suggesting vesicular
glutamate and non-vesicular
GABA origins for these effects. In addition, blockade of NAc GABAB receptors by
2-hydroxy-saclofen itself elevated NAc extracellular
glutamate. Intra-NAc perfusion of
2-hydroxy-saclofen not only abolished the enhanced extracellular
glutamate normally produced by
AMN082, but also decreased extracellular
glutamate in a TTX-resistant manner. We interpret these findings to suggest that the increase in
glutamate is secondary to the decrease in
GABA, which overcomes
mGluR7 activation-induced inhibition of non-vesicular
glutamate release. In contrast to its modulatory effect on
GABA and
glutamate, the
mGluR7 receptor does not appear to modulate NAc DA release.